Giant Biotech (02367) rose by more than 5%. As of press time, it rose 5.51% to HK$45.95, with a turnover of HK$76.93 million.
The Zhitong Finance App learned that Giants Biotech (02367) rose by more than 5% and rose 5.51% at press time to HK$45.95, with a turnover of HK$76.93 million.
In terms of performance, the company's results for the year ended December 31, 2023. The group obtained revenue of 3,524 billion yuan (RMB, same below) during the period, an increase of 49% over the previous year; profit attributable to owners of the parent company was 1,452 million yuan, an increase of 44.9% over the previous year; basic profit of 1.49 yuan per share; and a proposed final dividend of 0.44 yuan per common share and a special dividend of 0.45 yuan per common share. The company's recombinant collagen molecular library already has more than 40 types of collagen molecules, and the number remains leading in the industry. By the end of the reporting period, the Group had more than 100 ongoing research projects. During the reporting period, the Group successfully promoted the development and registration of 4 recombinant collagen skin revitalization products.
According to a research report released by CITIC Securities, the recombinant collagen industry has broad room for growth. Technological progress and process innovation at different links in the recombinant collagen preparation chain will bring low-cost recombinant collagen with better performance and diverse functions, drive the expansion of existing popular tracks (skincare/functional dressing/medical and aesthetic injections) and the enrichment of new downstream scenarios (anti-hair loss, intimate health & medical and aesthetic/serious medical/overseas travel, etc.). International skincare and medical leaders are developing recombinant collagen products one after another, and China's recombinant collagen raw materials have also begun a journey overseas. At the same time, the strengthening of industry regulations will promote the rapid and healthy development of the industry, and we are optimistic about the recombinant collagen industry.